Did Stoke’s New R&D Chair Signal a Tighter Late-Stage Focus for STOK’s Pipeline Strategy?
Stoke Therapeutics recently expanded its Board of Directors to ten members and appointed G. Clare Kahn, Ph.D., as…
Browsing Category